"10.1371_journal.pone.0144022","plos one","2015-12-03T00:00:00Z","Anna Sze Tai; Scott Cameron Bell; Timothy James Kidd; Ella Trembizki; Cameron Buckley; Kay Annette Ramsay; Michael David; Claire Elizabeth Wainwright; Keith Grimwood; David Mark Whiley","Queensland Children’s Medical Research Institute, Children’s Health Queensland, South Brisbane, Queensland, Australia; Adult Cystic Fibrosis Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia; School of Medicine, The University of Queensland, Herston, Queensland, Australia; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; Centre for Infection and Immunity, Queen’s University Belfast, Belfast, United Kingdom; School of Population Health, The University of Queensland, Herston, Queensland, Australia; Department of Respiratory and Sleep Medicine, Lady Cilento Children’s Hospital, South Brisbane, Queensland, Australia; Menzies Health Institute Queensland, Griffith University and the Gold Coast University Hospital, Gold Coast, Queensland, Australia; Pathology Queensland Central Laboratory, Herston, Queensland, Australia","Conceived and designed the experiments: AT SB TK CW KG DW. Performed the experiments: AT ET CB KR. Analyzed the data: AT SB TK ET CB KR MD KG DW. Contributed reagents/materials/analysis tools: AT DW TK KR SB. Wrote the paper: AT SB KG DW TK MD CW.","CEW declares income on a per patient basis derived from Pharmaceutical Studies - Vertex Pharmaceuticals Inc., & Boehringer-Ingelheim; Epidemiological Research Support from GlaxoSmithKline - Analysis of Bronchoalveolar lavage (BAL) fluid from children with respiratory disorders (2010 – 2012); Research Grant from Novo Nordisk Pharmaceuticals P/L- CF-IDEA Study. 2012–2013; and other reimbursement, as follows: Vertex Pharmaceuticals Inc. - Consultant on the Vertex Physician Pediatric CF Advisory Board and the Vertex Innovation Awards (VIA) Grants Committee; Gilead Sciences, Inc. - AZLI Advisory Board Honorarium 2010; Medscape - Consultation interview regarding CF Studies 2012; Vertex Pharmaceuticals 2013 San Francisco return flight and accommodation as Investigator in Lumacaftor study (104); Vertex Pharmaceuticals 2014 return flight and accommodation + honorarium as invited speaker at European CF Conference, Gothenburg, Sweden; Vertex Pharmaceuticals 2015 honorarium as speaker at a Vertex sponsored educational meeting series; Vertex Pharmaceuticals 2015 Chicago return flight and accommodation as Investigator in Lumacaftor study (109); Novartis Pharmaceuticals 2013 return travel and accommodation to give a symposium at European CF Conference in Lisbon; Novartis Pharmaceuticals Australia P/L 2013 honorarium to present symposium at Australasian CF Conference in Auckland; Novartis Pharmaceuticals 2014 return flight and accommodation + honorarium as invited speaker at National Pediatric Congress in Lebanon; Current Board Positions - Thorax Editorial Board /Associate Editor Respirology/ International Advisory Board Vertex Pharmaceuticals P/L. These do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.","2015","12","Anna Sze Tai","AST",10,TRUE,6,4,9,7,TRUE,TRUE,FALSE,0,NA,FALSE
